Efficacy of combining posterior scleral contraction and intravitreal C₃F₈ injection in high myopia with macular hole retinal detachment.

IF 1.9 4区医学 Q2 OPHTHALMOLOGY

International journal of ophthalmology Pub Date : 2025-06-18 eCollection Date: 2025-01-01 DOI:10.18240/ijo.2025.06.14

Si Chen, Jie Ye, Qin-Tuo Pan, Fang Huang, Lin-Yan Zheng, Hui-Fang Ye, Yan-Feng Su, Yan Li, Shuang-Qian Zhu

{"title":"Efficacy of combining posterior scleral contraction and intravitreal C3F8 injection in high myopia with macular hole retinal detachment.","authors":"Si Chen, Jie Ye, Qin-Tuo Pan, Fang Huang, Lin-Yan Zheng, Hui-Fang Ye, Yan-Feng Su, Yan Li, Shuang-Qian Zhu","doi":"10.18240/ijo.2025.06.14","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate the efficacy and safety of combining posterior scleral contraction (PSC) with intravitreal perfluoropropane (C3F8) injection in high myopia with macular hole retinal detachment (MHRD).Methods: A total of 22 participants (22 eyes) with high myopia [axial length (AL)≥26.5 mm] and MHRD who underwent PSC combined with intravitreal C3F8 injection, with at least 6mo of follow-up were retrospectively recruited. Outcome measures included best-corrected visual acuity (BCVA), AL, optical coherence tomography (OCT) findings, and adverse events. Retinal recovery was categorized as type I (macular hole bridging with retinal reattachment) or type II (reattachment without hole bridging).Results: The mean age of participants was 62.1±8.8y and mean follow-up duration was 9.18±4.21mo. Complete retinal reattachment was observed in 11 eyes (50%) at postoperative day 1, 19 eyes (86.3%) at week 1, and all 22 eyes at month 1. Ten eyes (45.5%) achieved type I recovery and 12 eyes (54.5%) achieved type II. Mean BCVA improved from 1.68±0.84 logMAR before surgery to 1.21±0.65 logMAR after surgery (P<0.001), and AL was significantly reduced compared to baseline (29.07±2.05 vs 30.8±2.2 mm; P<0.001). No serious complications were reported.Conclusion: PSC combined with intravitreal C3F8 injection is a safe and effective treatment for MHRD in highly myopic eyes, especially for retinal detachment limited within the vascular arcade.","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 6","pages":"1077-1084"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12120467/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.06.14","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate the efficacy and safety of combining posterior scleral contraction (PSC) with intravitreal perfluoropropane (C₃F₈) injection in high myopia with macular hole retinal detachment (MHRD).

Methods: A total of 22 participants (22 eyes) with high myopia [axial length (AL)≥26.5 mm] and MHRD who underwent PSC combined with intravitreal C₃F₈ injection, with at least 6mo of follow-up were retrospectively recruited. Outcome measures included best-corrected visual acuity (BCVA), AL, optical coherence tomography (OCT) findings, and adverse events. Retinal recovery was categorized as type I (macular hole bridging with retinal reattachment) or type II (reattachment without hole bridging).

Results: The mean age of participants was 62.1±8.8y and mean follow-up duration was 9.18±4.21mo. Complete retinal reattachment was observed in 11 eyes (50%) at postoperative day 1, 19 eyes (86.3%) at week 1, and all 22 eyes at month 1. Ten eyes (45.5%) achieved type I recovery and 12 eyes (54.5%) achieved type II. Mean BCVA improved from 1.68±0.84 logMAR before surgery to 1.21±0.65 logMAR after surgery (P<0.001), and AL was significantly reduced compared to baseline (29.07±2.05 vs 30.8±2.2 mm; P<0.001). No serious complications were reported.

Conclusion: PSC combined with intravitreal C₃F₈ injection is a safe and effective treatment for MHRD in highly myopic eyes, especially for retinal detachment limited within the vascular arcade.

查看原文本刊更多论文

巩膜后收缩联合玻璃体注射C3F8治疗高度近视伴黄斑孔视网膜脱离的疗效观察。

目的：评价巩膜后收缩（PSC）联合全氟丙烷（C3F8）玻璃体内注射治疗高度近视伴黄斑孔视网膜脱离（MHRD）的疗效和安全性。方法：回顾性招募22例（22只眼）高度近视[眼轴长(AL)≥26.5 mm]和MHRD患者，行PSC联合玻璃体内注射C3F8，随访至少6个月。结果测量包括最佳矫正视力（BCVA）、AL、光学相干断层扫描（OCT）结果和不良事件。视网膜恢复分为I型（黄斑孔桥接合并视网膜再附着）和II型（再附着无孔桥接）。结果：参与者平均年龄为62.1±8.8岁，平均随访时间为9.18±4.21个月。术后第1天有11眼（50%）视网膜完全复位，第1周有19眼（86.3%）视网膜完全复位，第1个月22眼视网膜完全复位。10眼（45.5%）达到I型恢复，12眼（54.5%）达到II型恢复。平均BCVA由术前的1.68±0.84 logMAR改善至术后的1.21±0.65 logMAR (vs 30.8±2.2 mm；结论：PSC联合玻璃体内注射C3F8治疗高度近视眼MHRD是一种安全有效的治疗方法，尤其对局限于血管拱廊内的视网膜脱离更为有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of ophthalmology Medicine-Ophthalmology

CiteScore

2.50

自引率

7.10%

发文量

3141

审稿时长

4-8 weeks

期刊介绍： · International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online). This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed, PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166. IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO); Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President, Chinese Academy of Engineering. International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of AAO/PAAO) et al. Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society). Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press). Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics). Associate Editors-in-Chief include: Prof. Ning-Li Wang (President Elect of APAO); Prof. Ke Yao (President of Chinese Ophthalmological Society) ; Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ; Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA); Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society); Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA); Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA). IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles, both basic and clinical papers. Instruction is Welcome Contribution is Welcome Citation is Welcome Cooperation organization International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.